디앤디파마텍

347850KOSDAQ자연과학 및 공학 연구개발업

59.1 / 100

Reference Date: 2026-06-10

Financial Score11.0 / 40

News Sentiment20.1 / 25

Momentum18.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Surged 27.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

D&D Pharmatech is a biopharmaceutical company specializing in developing innovative drugs for metabolic diseases, such as obesity and MASH (metabolic-associated steatohepatitis), and neurodegenerative disorders like Parkinson's and Alzheimer's, leveraging GLP-1-based peptide technology. The company's key pipelines include oral weight-loss medications and MASH treatments, with a business model focused on licensing and co-development with global partners. Additionally, it expands into areas such as PET biomarker development and alpha radiation-based cancer therapies through its subsidiaries.

Number of Employees

22people

Average Salary

169.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

—Industry Average 3.243.5Point

ROE

-32.29Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

16.64Industry Average 7.310.0Point

2.3x industry avg (risky)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼62.4% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼35.9% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -39.8% (improving, 2yr)

Detailed News Sentiment

18 totalPositive 16Neutral 1Negative 1Average Sentiment Score 80.3

Positive
건강 종합 관리로, 비만약 진화 길 잡았다
디앤디파마텍 관련 연구가 당뇨병 치료 분야에서 혁신적인 진전을 보여주며 긍정적인 시장 반응을 이끌어냈다.
Positive
디앤디파마텍, 빅딜 기대감에 '강세'…에임드바이오·이뮨온시아 ↓[...
디앤디파마텍의 대사이상 관련 지방간염 기술이전 기대감으로 강세를 보임.
Negative
코스피, 8600선 약세 마감…외국인 7조 순매도
외국인의 지속적인 순매도가 코스피 하락을 초래하여 디앤디파마텍 주가에도 부정적 영향을 미쳤다.

Detailed Momentum

52-week position6.0Point

52w upper range (76%)

Current 89,600Won52-week high 110,00052-week low 21,371

1-month return6.0Point

1m +27.64% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
Neutral기업설명회(IR)개최2026-06-05
Neutral기업설명회(IR)개최2026-06-02